Ketek Drug Alert Information Center: __________________ Bronchitis Drug - Ketek - May Cause Liver Failure Information and Warnings about the drug Ketek Ketek Side Effects and Dangers Liver Failure, Liver Damage and Hepatitis Drug Alert - Ketek Ketek Drug Alert Update The Facts about Ketek We will work under a Contingency Fee Contract

Did you know or were you aware that severe liver damage, known as hepatoxicity, which in some cases leading to liver transplant or death, has been reported in patients being treated with the antibiotic drug Ketek. Three cases of liver toxicity in patients taking Ketek antibiotic were reported to FDA as detailed and reported in an article in the Annals of Internal Medicine. Examination of these patients' livers showed massive tissue death. All patients had been healthy previous to the use of Ketek and were not using other prescription drugs.  These instances of acute hepatic failure and severe liver injury were observed either during, even after only a few doses, or immediately after treatment. In addition, less severe hepatic dysfunction associated with increased liver enzymes, hepatitis and in some cases jaundice was reported with the use of Ketek. These events associated with less severe forms of liver toxicity were reversible.

The most common injures of the drug Ketek are gastrointestinal; diarrhea, nausea, abdominal pain and vomiting. Headache and disturbances in taste also occur. Less common side-effects include palpitations, blurred vision and rashes. Patients using Ketek should be aware of the potential signs or symptoms of hepatitis, such as fatigue, malaise, anorexia, nausea, jaundice, bilirubinuria (presence of bile in urine), acholic (pale or clay-colored) stools, liver tenderness or hepatomegaly (enlargement). Ketek antibiotic has also been found to exacerbate Myasthenia Gravis, an autoimmune disorder that causes progressive muscle weakening. There have been reports of fatal and life-threatening respiratory failure in patients with myasthenia gravis and its use in such patients is therefore contraindicated.

Ketek, is sold as a generic as telithromycin, is an antibiotic used for the treatment of respiratory infections including chronic bronchitis, acute bacterial sinusitis and community-acquired pneumonia. Ketek is manufactured by the French pharmaceutical giant Sanofi-Aventis. Telithromycin is administered as tablets. Two 400mg tablets to be taken together, daily, with or without food. It prevents bacteria growth, by interfering with its protein synthesis.

A United States Congressional investigation is attempting to determine why the drug was approved even after a physician was convicted of fraud in clinical trials of Ketek. The initial new drug application for telithromycin was rejected by the FDA in June, 2001, citing a request for additional safety data regarding liver injuries, blurred vision, and other possible side effects. Based on these concerns, the FDA ordered Sanofi to conduct further safety tests. Additionally, the FDA uncovered some problems with Sanofi's Study 3014 with have resulted in the imprisonment of the lead subject ruecruiting physician, who recruited 414 subjects, at $400 each according to the contract introduced in evidence at her trial. She is now in federal prison after pleading guilty to fraud resulting from the fabrication of data.

Internal corporate documents reviewed by The Wall Street Journal indicate the company's concern with its highest recruiter, but the concerns were not disclosed to the FDA. The second-high enroller (251 patients) was found during an FDA audit to have not followed the protocol or reported adverse drug reactions. The third-highest recruiter (214 patients) was, at the time, working with a probationary license under sanction of a state disciplinary board; the FDA audit found evidence of records altered with "white-out."  What is perhaps most outrageous about the entire sad affair is that Study 3014 was specifically mandated to investigate liver toxicity. Now, after being on the market for two years, there is new evidence that Ketek is harmful to the liver. A recent analysis of the FDA's post-marketing database showed that the rate of reporting of acute liver failure was 3.5 to 11 times as high for Ketek as for other antibiotics, with a reporting rate of 167 cases of acute liver failure per 1 million person years of telithromycin use, as compared with the expected rate of 1 case per 1 million person-years.

If you or a family member have suffered a loss as a result of the use of this drug call us toll free at 1-800-862-1260.

TRADEMARK NOTICE: Ketek is a trademark of Sanofi-Aventis, Inc.

The Carabin & Shaw Law Firm, its' lawyers and this website is in no way affiliated with Sanofi-Aventis, Inc. The use of this mark is solely for informational and product identification purposes.